Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: ADENURIC
Active substances:
Estonian, English, Latin
ATC code: M04AA03
Dosage form: film-coated tablet
Strength: 120mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Indication: ADENURIC is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). ADENURIC is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS). ADENURIC is indicated in adults.
Safety features: Yes
Marketing authorization holder: Menarini International Operations Luxembourg S.A. 
Marketing authorization number: EU/1/08/447 
Marketing authorization issued on: April 21, 2008 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1349300  ADENURIC  film-coated tablet  120mg 28TK  Prescription  100% 90% 50% 75%  11,76  09.11.2023     
1349311  ADENURIC  film-coated tablet  120mg 84TK  Prescription           
1493007  ADENURIC  film-coated tablet  120mg 14TK  Prescription           
1493018  ADENURIC  film-coated tablet  120mg 42TK  Prescription           
1493029  ADENURIC  film-coated tablet  120mg 56TK  Prescription           
1493030  ADENURIC  film-coated tablet  120mg 98TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere